252 related articles for article (PubMed ID: 31871301)
1. Everolimus Inhibits the Progression of Ductal Carcinoma
Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ
Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301
[TBL] [Abstract][Full Text] [Related]
2. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
[TBL] [Abstract][Full Text] [Related]
3. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
[TBL] [Abstract][Full Text] [Related]
5. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
6. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
7. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
[TBL] [Abstract][Full Text] [Related]
9. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
[TBL] [Abstract][Full Text] [Related]
11. Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.
Duivenvoorden HM; Rautela J; Edgington-Mitchell LE; Spurling A; Greening DW; Nowell CJ; Molloy TJ; Robbins E; Brockwell NK; Lee CS; Chen M; Holliday A; Selinger CI; Hu M; Britt KL; Stroud DA; Bogyo M; Möller A; Polyak K; Sloane BF; O'Toole SA; Parker BS
J Pathol; 2017 Dec; 243(4):496-509. PubMed ID: 29086922
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778
[TBL] [Abstract][Full Text] [Related]
13. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
14. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
15. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.
Bi X; Hameed M; Mirani N; Pimenta EM; Anari J; Barnes BJ
Breast Cancer Res; 2011; 13(6):R111. PubMed ID: 22053985
[TBL] [Abstract][Full Text] [Related]
16. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
17. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS).
Farnie G; Johnson RL; Williams KE; Clarke RB; Bundred NJ
Cell Cycle; 2014; 13(3):418-25. PubMed ID: 24247151
[TBL] [Abstract][Full Text] [Related]
19. Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.
Valdez KE; Fan F; Smith W; Allred DC; Medina D; Behbod F
J Pathol; 2011 Dec; 225(4):565-73. PubMed ID: 22025213
[TBL] [Abstract][Full Text] [Related]
20. Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function.
Sarper M; Allen MD; Gomm J; Haywood L; Decock J; Thirkettle S; Ustaoglu A; Sarker SJ; Marshall J; Edwards DR; Jones JL
Breast Cancer Res; 2017 Mar; 19(1):33. PubMed ID: 28330493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
